Related Experiment Video

Updated: Jun 20, 2026

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats
07:36

Modeling Encephalopathy of Prematurity Using Prenatal Hypoxia-ischemia with Intra-amniotic Lipopolysaccharide in Rats

Published on: November 20, 2015

Higher cumulative doses of erythropoietin and developmental outcomes in preterm infants

Mark S Brown1, Delphine Eichorst, Brenda Lala-Black

  • 1Department of Pediatrics, Eastern Maine Medical Center, 489 State St, Kelley 6, Bangor, ME 04401, USA. mbrown@emh.org

Pediatrics
|September 30, 2009
PubMed

Insights

Higher cumulative doses of recombinant erythropoietin (rEPO) in preterm infants were linked to improved Mental Developmental Index (MDI) scores. This suggests a potential benefit of rEPO for neurodevelopmental outcomes in this vulnerable population.

Area of Science:

  • Neonatal Medicine
  • Developmental Pediatrics
  • Pharmacology

Background:

  • Extremely preterm infants face significant risks for developmental delays.
  • Recombinant erythropoietin (rEPO) is used in neonates, but its impact on long-term neurodevelopment is under investigation.
  • Previous studies have explored rEPO's effects on retinopathy of prematurity.

Purpose of the Study:

  • To investigate the association between cumulative doses of rEPO administered during the first six postnatal weeks and developmental outcomes in extremely preterm infants.
  • To determine if higher rEPO doses correlate with improved scores on the Bayley Scales of Infant Development-II Revised.

Main Methods:

  • Retrospective cohort study of 366 infants (<1500g, ≤30 weeks gestation).
  • Included infants with developmental follow-up evaluations at >12 months corrected age.
  • Multivariate linear regression analyses assessed associations between rEPO doses and Bayley Scales scores (PDI and MDI).

Main Results:

  • Developmental evaluations were available for 82 infants (median age 25 months).
  • Higher cumulative rEPO dose in the first 6 weeks was associated with improved Mental Developmental Index (MDI) scores (R² = 0.40).
  • Psychomotor Developmental Index (PDI) scores were associated with transfusions, female gender, birth weight, and Apgar scores (R² = 0.39).

Conclusions:

  • A dose-response relationship exists between rEPO treatment and enhanced MDI scores in extremely preterm infants.
  • Findings align with adult studies and animal models of brain injury.
  • Further research is needed to confirm these developmental benefits of rEPO.
Abstract

More Related Videos

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis06:19

A Rat Model of Mild Intrauterine Hypoperfusion with Microcoil Stenosis

Published on: January 7, 2018

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo08:53

A Comprehensive Pipeline to Assess the Efficiency of Human Erythropoiesis In Vitro and Ex Vivo

Published on: January 10, 2025

Related Concept Videos

Factors Affecting Erythropoiesis01:24

Factors Affecting Erythropoiesis

The cardiovascular system regulates the number of erythrocytes in the bloodstream to ensure optimal oxygen transport. It also prevents over-proliferation of these cells, which helps to maintain blood viscosity and flow rate.
Several factors influence the erythrocyte production rate, with tissue oxygen level being among the most critical. Intense exercise or high altitudes can cause tissue hypoxia, which triggers the kidneys to release more erythropoietin (EPO) into the bloodstream.
EPO then...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Erythropoiesis01:14

Erythropoiesis

Red blood cells  (RBCs) transport oxygen to all body tissues. These cells survive only for 120 days and then need to be replenished. Erythropoiesis is the process of RBC production. In healthy individuals, erythropoiesis ensures all tissues are amply supplied with oxygen. In addition, blood loss due to injury leads to a drop in the physiological oxygen level that will cause erythropoiesis. Any defect in erythropoiesis leads to several physiological disorders, including thalassemia, anemia, and...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...